Matthew L. Posard
Director at Halozyme Therapeutics; Director at Nautilus Biotechnology. Based in San Diego, California.
- Rank
- 14596th of 14,644
- Companies held
- 2
- Largest holding
- HALO, 93.3% of total
- Latest SEC filing
- Nov 18, 2026
What the $4.8M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Halozyme Therapeutics HALO Common Stock | Directly | 48,609 | $93.04 | $4.5M | 93.3% | Form 4, Nov 18, 2026 |
| Nautilus Biotechnology NAUT Common Stock | Indirectly (see filing footnote) | 100,000 | $2.17 | $217K | 4.5% | Form 4, Nov 30, 2021 |
| Nautilus Biotechnology NAUT Common Stock | Directly | 50,000 | $2.17 | $109K | 2.2% | Form 4, Dec 1, 2021 |
Share counts are the amounts Matthew L. Posard reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Sold | HALO | 3,400 | $96.17 | $327K | View |
| Nov 18, 2026 | Sold | HALO | 1,600 | $96.97 | $155K | View |
| Oct 1, 2026 | Sold | HALO | 730 | $107.17 | $78K | View |
| Oct 1, 2026 | Sold | HALO | 3,300 | $108.45 | $358K | View |
| Oct 1, 2026 | Sold | HALO | 1,100 | $109.57 | $121K | View |
| Oct 1, 2026 | Sold | HALO | 100 | $110.04 | $11K | View |
| Sep 16, 2026 | Sold | HALO | 3,000 | $106.83 | $320K | View |
| Sep 16, 2026 | Sold | HALO | 8,896 | $108.04 | $961K | View |
| Sep 16, 2026 | Sold | HALO | 3,100 | $106.13 | $329K | View |
| Sep 16, 2026 | Sold | HALO | 4,000 | $108.99 | $436K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 14593 | Horne Edward Van President & COO, GMR Solutions. Lewisville, TX | $4.9M |
| 14594 | Jula Inrig EVP, Head of R&D & CMO, Travere Therapeutics. San Diego, CA | $4.9M |
| 14595 | Christopher L. Finazzo Chief Commercial Officer, United Parks & Resorts. Orlando, FL | $4.9M |
| 14596 | Matthew L. Posard Director, Halozyme Therapeutics. San Diego, CA | $4.8M |
| 14597 | Edward W. Rabin Director, Sally Beauty Holdings. Denton, TX | $4.8M |
| 14598 | Jerry C. Jones Director, Agilysys. Alpharetta, GA | $4.8M |
| 14599 | Craig Saldanha Chief Product Officer, Yelp. San Francisco, CA | $4.8M |
Other Halozyme Therapeutics insiders
All HALO insiders- Helen Torley$71.4MPRESIDENT AND CEO. #1959 overall
- Connie Matsui$17.0MDirector. #5832 overall
- Michael J. LaBarre$16.2MSVP, CHIEF TECHNICAL OFFICER. #6058 overall
- Jean-Pierre Bizzari$6.2MDirector. #12191 overall
- Jeffrey William Henderson$3.4MDirector. #10173 overall
- David A. Ramsay$427KEVP, PRESIDENT, DRUG DELIVERY. #6945 overall
Questions
How much stock does Matthew L. Posard own?
Matthew L. Posard holds $4,848,081 in listed stock based on SEC filings and current prices, mostly Halozyme Therapeutics (HALO). That ranks 14596th on the Stock Rich List.
Is this Matthew L. Posard's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Matthew L. Posard last buy or sell stock?
The most recent open-market trade on file is a sale of 3,400 HALO shares on Nov 18, 2026 at $96.17.